Literature DB >> 16552809

Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.

Roberto-Giulio Romanelli1, Giorgio La Villa, Giuseppe Barletta, Francesco Vizzutti, Fabio Lanini, Umberto Arena, Vieri Boddi, Roberto Tarquini, Pietro Pantaleo, Paolo Gentilini, Giacomo Laffi.   

Abstract

AIM: To investigate the effects of long-term albumin administration on survival, recurrence of ascites and onset of other complications.
METHODS: One hundred consecutive patients admitted for first-onset ascites were randomized to receive diuretics plus human albumin 25 g/wk in the first year and 25 g every two wk thereafter (group 1) or diuretics alone (group 2). The primary endpoint was survival without liver transplantation. Secondary endpoints were recurrence of ascites and occurrence of other complications.
RESULTS: Median follow-up was 84 (2-120) mo. Albumin-treated patients had significantly greater cumulative survival rate (Breslow test=7.05, P=0.0078) and lower probability of ascites recurrence (51% versus 94%, P<0.0001). Chronic albumin infusion resulted in a mean increase in survival of 16 mo.
CONCLUSION: Long-term albumin administration after first-onset ascites significantly improves patients' survival and decreases the risk of ascites recurrence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552809      PMCID: PMC4124318          DOI: 10.3748/wjg.v12.i9.1403

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  The effect of repeated albumin infusions in patients with cirrhosis.

Authors:  P WILKINSON; S SHERLOCK
Journal:  Lancet       Date:  1962-12-01       Impact factor: 79.321

Review 2.  The use of albumin in clinical practice.

Authors:  B L Erstad; B J Gales; W D Rappaport
Journal:  Arch Intern Med       Date:  1991-05

3.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites.

Authors:  J Llach; P Ginès; V Arroyo; A Rimola; L Titó; S Badalamenti; W Jiménez; J Gaya; F Rivera; J Rodés
Journal:  Gastroenterology       Date:  1988-02       Impact factor: 22.682

4.  Survival and prognostic indicators in compensated and decompensated cirrhosis.

Authors:  G D'Amico; A Morabito; L Pagliaro; E Marubini
Journal:  Dig Dis Sci       Date:  1986-05       Impact factor: 3.199

5.  Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study.

Authors:  R Planas; P Ginès; V Arroyo; J Llach; J Panés; V Vargas; J M Salmerón; A Ginès; C Toledo; A Rimola
Journal:  Gastroenterology       Date:  1990-12       Impact factor: 22.682

6.  The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards.

Authors:  P Gentilini; M Bernardi; L Bolondi; A Craxi; G Gasbarrinie; G Ideo; G Laffi; G La Villa; F Salerno; E Ventura; A Pulazzini; L Segantini; R G Romanelli
Journal:  Dig Liver Dis       Date:  2004-08       Impact factor: 4.088

7.  Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid.

Authors:  Rajiv Jalan; Dharmesh Kapoor
Journal:  Clin Sci (Lond)       Date:  2004-05       Impact factor: 6.124

8.  Compensated cirrhosis: natural history and prognostic factors.

Authors:  P Ginés; E Quintero; V Arroyo; J Terés; M Bruguera; A Rimola; J Caballería; J Rodés; C Rozman
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

9.  Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites.

Authors:  F Salerno; S Badalamenti; E Lorenzano; P Moser; P Incerti
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

Review 10.  Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

Authors:  R W Schrier; V Arroyo; M Bernardi; M Epstein; J H Henriksen; J Rodés
Journal:  Hepatology       Date:  1988 Sep-Oct       Impact factor: 17.425

View more
  35 in total

Review 1.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 2.  Clinical use of albumin.

Authors:  Paolo Caraceni; Manuel Tufoni; Maria Elena Bonavita
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 3.  Clinical use of albumin in hepatology.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Antonio Gasbarrini
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

4.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

5.  5 Human Albumin.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

6.  AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Pierluigi Berti; Francesco Bennardello; Francesco Fiorin; Pierluigi Piccoli
Journal:  Blood Transfus       Date:  2020-12-18       Impact factor: 3.443

7.  How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure.

Authors:  Federica Mirici-Cappa; Paolo Caraceni; Marco Domenicali; Ernesto Gelonesi; Barbara Benazzi; Giacomo Zaccherini; Franco Trevisani; Cristina Puggioli; Mauro Bernardi
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

8.  Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference.

Authors:  Manuel Tufoni; Giacomo Zaccherini; Paolo Caraceni
Journal:  Ann Transl Med       Date:  2019-09

Review 9.  Albumin in chronic liver disease: structure, functions and therapeutic implications.

Authors:  Rosaria Spinella; Rohit Sawhney; Rajiv Jalan
Journal:  Hepatol Int       Date:  2015-09-29       Impact factor: 6.047

Review 10.  Role of human albumin in the management of complications of liver cirrhosis.

Authors:  Mauro Bernardi; Carmen S Ricci; Giacomo Zaccherini
Journal:  J Clin Exp Hepatol       Date:  2014-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.